Photo from wikipedia
The discovery of ALK rearrangements in non-small cell lung cancer (NSCLC) and their oncogenic properties by Soda et al . in 2007 gave the start to one of the most… Click to show full abstract
The discovery of ALK rearrangements in non-small cell lung cancer (NSCLC) and their oncogenic properties by Soda et al . in 2007 gave the start to one of the most famous stories in the treatment of lung cancer (1). Diagnosed in around 5% of patients with NSCLC, ALK rearrangements are effectively treated with the ALK-directed tyrosine kinase inhibitor (ALK-TKI) crizotinib (2,3).
Keywords:
alk;
rearrangements created;
alk rearrangements;
cancer;
created equal
Journal Title: Translational cancer research
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Translational cancer research
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!